-
Gilead Partners with Assembly Biosciences in $84.8 Million Collaboration for Antiviral Therapies
Gilead Sciences (NASDAQ: GILD) has announced a significant 12-year collaboration with antiviral specialist Assembly Biosciences (NASDAQ: ASMB) aimed at developing innovative therapies targeting herpesviruses, hepatitis B virus (HBV), and hepatitis D virus (HDV). This partnership allows Gilead to acquire Assembly’s promising programs, which include a next-generation core inhibitor for HBV,…
